×
ADVERTISEMENT

Krazati

FDA Grants Accelerated Approval to Krazati With Erbitux for KRAS G12C–Mutated Colorectal Cancer

The FDA has granted accelerated approval to adagrasib (Krazati, Mirati Therapeutics) plus cetuximab (Erbitux, ...

JUNE 24, 2024

Load more